<![CDATA[Where MRD Testing Fits Into Myeloma’s Treatment and Regulatory Landscape]]>

RegulatoryapprovedPositive

AI Analysis

Summary

The FDA has endorsed minimal residual disease (MRD) testing as an accelerated approval endpoint in multiple myeloma treatment. This regulatory recognition impacts how myeloma therapies will be evaluated in clinical development and regulatory pathways.

Outcome Details

FDA endorsed MRD (minimal residual disease) testing as an accelerated approval endpoint in multiple myeloma

Importance:6/10

Sentiment:

0.70

MRD testingmultiple myelomaaccelerated approvalregulatoryendpoint

Read the original article

Published by Cancer Network on September 29, 2026 2:00 PM

Read Original